National Instruments Co.

Miata Metals Files NI43-101 Technical Report on Sela Creek Gold Project in Suriname September 17, 2024 10:32 AM EDT | Source: Miata Metals Corp. Vancouver, British Columbia--(Newsfile Corp. - September 17, 2024) - Miata Metals Corp. (CSE: MMET) (FSE: 8NQ) ("Miata" or the "Company") is pleased to announce that it has voluntarily filed a technical report on the Sela Creek gold project in Suriname titled "Technical Report Sela Creek Gold Project, Sipaliwini District, Suriname, South America" (the "Report"). The Report, dated July 3, 2024, is prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101"), and is authored by Dennis J. LaPoint, Ph.D. (the "Author") of Appalachian Resources LLC, and is available under the Company's SEDAR profile on http://www.sedarplus.ca. Dr. LaPoint is an independent Qualified Person as defined by NI 43-101, and has managed and conducted multiple exploration programs throughout Suriname.About Miata Metals Corp.Miata Metals Corp. (CSE: MMET). is a Canadian mineral exploration company listed on the Canadian Securities Exchange. The Company is focused on the acquisition, exploration, and development of mineral properties. Currently, the Company holds earn-in options to acquire 100% interest in the Sela Creek Gold Project in Suriname and 100% interest in the Cabin Lake Property in the Omineca Mining Division, British Columbia. The Company continuously evaluates opportunities to acquire interest in additional prospective exploration stage mineral properties. On Behalf of the BoardDr. Jacob (Jaap) Verbaas, P.Geo | CEO and [email protected]+1 778 488 9754The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223610 SOURCE: Miata Metals Corp. » Mehr auf newsfilecorp.com

HDT bio's Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ -- HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud to announce its pivotal role in PROVIDENT (Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics Against Diverse Emerging Infectious Threats), a national consortium led by Albert Einstein College of Medicine and funded by the National Institute of Allergy and Infectious Diseases (NIAID) as part of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network. HDT Bio will focus on developing "road maps" for the rapid creation of RNA vaccines against pathogens with pandemic potential, harnessing the company's proprietary AMPLIFY™ self-amplifying replicon RNA (repRNA) platform and LION™ nanoparticle delivery system. The combination of these two technologies offers increased vaccine potency, durability, and stability, while simplifying production—critical features for addressing emerging infectious threats quickly and effectively. "We are excited to contribute our expertise in RNA vaccine technologies to the PROVIDENT consortium," said Steve Reed, Ph.D., Chief Executive Officer of HDT Bio. "Our AMPLIFY™ and LION™ platforms have demonstrated their ability to rapidly generate potent, durable immune responses with a favorable safety profile. These innovations will be essential in preparing for future pandemics, where speed and flexibility in vaccine development will save lives." As part of the PROVIDENT initiative, HDT Bio will develop a comprehensive strategy to create RNA vaccines capable of targeting pathogens across multiple viral families, focusing particularly on rapid adaptability to emerging "virus X" scenarios. This aligns with PROVIDENT's broader goals of safeguarding public health by advancing platforms that can be quickly tailored to respond to novel viral threats. "It is currently unknown if the state-of-the-art approaches used to design vaccine antigens for traditional vaccine technologies can simply be co-opted for use in RNA vaccine technologies," said Jesse Erasmus, Ph.D., who is the principal investigator on the subaward. "In our project, Rapid-Response Roadmap for RNA vaccines, HDT Bio will address this unknown while generating prototype vaccine candidates for 8 different viruses across 3 virus families of pandemic potential, collaborating with other member institutions of PROVIDENT to design and characterize antigens using structure-guided and high-throughput mutagenesis approaches." "We will also evaluate safety and immunogenicity against a diverse panel of viruses, and characterize efficacy in high-containment," Dr. Erasmus added. The additional key contributors to these efforts at HDT Bio are: HDT Bio will work with 12 teams in academia and government alongside 3 other projects titled, 1) "Discovery and dissection of virus-host interactions and pathogenetic mechanisms", 2) "Antigen design and immunological evaluation", and 3) Mining human antibody responses to inform vaccine and therapeutic design". More details on collaborating institutions and their key researchers can be found in Albert Einstein College of Medicine's description of the parent award. HDT Bio's LION™/repRNA platform builds on the company's pioneering work in vaccine development, notably including emergency use authorizations for its vaccine during the COVID-19 pandemic. The company's innovative approach to RNA vaccine delivery, particularly through its LION™ nanotechnology, enhances the safety and efficacy of RNA-based vaccines while maintaining crucial logistical benefits such as refrigeration stability and simplified manufacturing. "Our role in PROVIDENT exemplifies HDT Bio's mission to make RNA vaccines a cornerstone of future pandemic preparedness," added Dr. Reed. "By working in concert with academic, government, and industry partners, we aim to provide the tools needed to address unknown viral threats quickly and efficiently." For more information on HDT Bio's AMPLIFY™ and LION™ platforms, visit www.hdt.bio. About HDT Bio HDT Bio is a Seattle-based, clinical-stage biopharmaceutical development company. With core technology and expertise in nucleic acid formulation, the company develops products that seek to harness host-directed immune responses. HDT Bio's work focuses on infectious disease and oncology vaccines and therapeutics through early-stage collaborations with partners worldwide. The company's vaccine platforms combine formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses. HDT Bio's repRNA/LION™ was the first self-amplifying RNA vaccine platform to ever receive a regulatory authorization. » Mehr auf prnewswire.com

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Silver Storm Mining Ltd. (“Silver Storm” or the "Company") (TSX.V: SVRS | OTCQB: SVRSF | FSE: SVR) announced today that it anticipates the filing of its annual financial statements, management's discussion and analysis and related officer certifications for the financial year ended March 31, 2024 (collectively, the “Annual Filings”) will be delayed beyond the required filing deadline under Parts 4 and 5 of National Instrument 51-102 - Continuous Disclosure Obligations and pursuant to National Instrument 52-109 - Certification of Disclosure in Issuer's Annual and Interim Filings, being July 29, 2024 (the “Filing Deadline”). » Mehr auf globenewswire.com